SingleSkin & Cosmetic

Argireline 10%

Topical hexapeptide engineered to emulate SNAP-25, investigated in cosmetic models for reducing the visual depth of expression lines.

Mechanism

Mimics the N-terminal region of SNAP-25 to reversibly compete for SNARE complex binding, inhibiting vesicle docking and attenuating acetylcholine release.

Dosing

Evaluated topically using a 5% to 10% solution applied as a thin layer to clean skin once or twice daily.

Reconstitution

Formulated directly as a ready-to-use topical solution or blended into cosmetic vehicles without the addition of bacteriostatic water.

Storage

Store in a light-resistant container in a cool environment, preferably refrigerated between 2°C and 8°C, while preventing freeze-thaw cycles.

Mix & measure Argireline 10%

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Argireline 10%

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration—

Draw volume—

On the syringe—

Total doses in vial: —

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Patch Test (Day 0)	Small test dab applied once	N/A (Topical application)
Weeks 1–4	5–10% solution applied twice daily	Thin layer (Topical leave-on)
Weeks 4–8	5–10% solution applied twice daily	Thin layer (Topical leave-on)
Maintenance	5–10% solution applied 1–2 times daily	Thin layer (Topical leave-on)

Reconstitution Steps

1
Verify whether the product is supplied as a finished 10% aqueous solution or raw lyophilized powder.
2
If working with raw powder, calculate the precise mass required to achieve a 3% to 10% concentration in a water-based cosmetic vehicle.
3
Gradually incorporate the peptide into the aqueous base or serum under sterile, room-temperature conditions until completely dissolved.
4
Ensure the final formulation maintains a slightly acidic to neutral pH (approximately 5.0 to 6.0) to preserve molecular stability.
5
Transfer the finished topical mixture into an airtight, opaque dropper bottle or dispenser to protect it from ambient oxidation and light exposure.

Supplies Needed

Peptide Vial

Provides research-grade Argireline (acetyl hexapeptide-8) solution or powder for topical investigation.

Insulin Syringes (U-100)

Not utilized for this compound; Argireline is strictly designated for topical application.

Bacteriostatic Water

Not required for standard cosmetic emulsions or topical vehicle formulations.

Alcohol Swabs

Used to sterilize external glassware, compounding tools, and container exteriors during preparation.

Why researchers study it

Expression-line appearance

Peptide skin penetration

Topical alternative interest

Formulation & stability

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Argireline, chemically designated as acetyl hexapeptide-8, is a synthetic peptide derived from the amino-terminal segment of SNAP-25. It is extensively evaluated within cosmetic pharmacology as a topical agent aimed at minimizing dynamic facial wrinkles, specifically periorbital and forehead lines caused by repetitive muscle movement. Unlike traditional neurotoxins that rely on deep parenteral delivery, Argireline is formulated exclusively for cutaneous, non-invasive study. In experimental and dermatological literature, Argireline is framed around finished formulation concentrations, typically between 5% and 10% of an aqueous solution, rather than discrete microgram metrics. Because the peptide operates via non-destructive competitive modulation rather than enzymatic cleavage, any observed effects on skin topography are transient and dependent on continued external application. Investigations into this compound heavily focus on topical delivery kinetics and formulation science. Due to its hydrophilic structure and high molecular mass relative to transdermal pathways, ongoing research aims to determine the extent to which it crosses the stratum corneum barrier to achieve localized extracellular concentration without systemic dispersion.

References

1.Blanes-Mira et al., International Journal of Cosmetic Science, 2002 — 10% hexapeptide emulsion reduced wrinkle depth with in-vitro neurotransmitter inhibition data
2.Wang et al., American Journal of Clinical Dermatology, 2013 — Placebo-controlled trial of 10% Argireline eye cream on skin roughness
3.Gorouhi & Maibach, International Journal of Cosmetic Science, 2009 — Review of topical bioactive peptides in aging skin
4.Blanes-Mira et al., Journal of Neurochemistry, 2004 — SNAP-25-derived peptides impair SNARE assembly and exocytosis
5.Kraeling et al., Cutaneous and Ocular Toxicology, 2015 — In-vitro stratum corneum penetration of acetyl hexapeptide-8
6.Hoppel et al., European Journal of Pharmaceutical Sciences, 2015 — Influence of topical vehicle formulation on hexapeptide penetration
7.Reddy et al., Experimental Dermatology, 2012 — Bioactive oligopeptides in cutaneous medicine and cosmetic science